Contents
Issue 140 • March 2024
In association with
In Depth
Biotechs surf obesity drug wave to go beyond GLP-1RAs
The opioid crisis: Different delivery systems tackle treatment needs
Pharma readies for climate disasters amidst supply chain concerns
CRISPR pipeline accelerates after milestone Casgevy approval
The future of cell and gene therapy manufacturing
Amgen showcases exciting potential in the obesity space at JPM24
Q&A: Regulatory reform necessary to improve obesity drug access
Novo to buy Catalent